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Question. To evaluate the relationship between maternal prescription opioid use and incidence of 
neurodevelopmental disorders in children.  
Findings. In this retrospective cohort study, 7.6% of eligible children were exposed to prescription 
opioids during pregnancy. We observed no overall association between maternal prescription opioid use 
and the risk of neurodevelopmental disorders in children. However, significantly increased risks were 
observed in children with longer-term opioid exposure or high cumulative doses.  
Meaning.  These findings suggest the need for a careful consideration of the benefits of opioid therapy 



















Importance. Little is known regarding long-term effects of fetal opioid exposure on the 
neurodevelopment of children.  
Objective. To quantify the association between prenatal opioid exposure from maternal prescription use 
and long-term neurodevelopmental outcomes in children.  
Design. Retrospective cohort study using administrative claims submitted to a large commercial 
insurance database. 
Setting and Participants. We included pregnant women aged 12 – 55 years and their live-birth infants 
born from 2010 to 2012 present in Optum’s deidentified Clinformatics® Data Mart Database. Infants 
born to eligible mothers were followed till occurrence of primary outcome, loss to follow-up, or study 
end (December 31, 2017), whichever came first. 
Exposures. Infants were considered exposed if their mothers filled ≥1 opioid prescription during 
pregnancy.  
Main outcomes and measures. The primary outcome was neurodevelopmental disorders; a composite 
of developmental disorders, intellectual disabilities, and other relevant mental disorders in children. 
Propensity score by fine-stratification was applied to adjust for confounding. Hazard ratios (HR) and 95% 
confidence intervals (CI) were estimated with Cox proportional hazard models. Sensitivity analyses were 
conducted to examine the effects of maternal opioid use by cumulative exposure dichotomized as short-
term (<14 days), by long-term use (≥14 days), cumulative dose (low dose: < 37.5 MME or high dose: 
≥37.5 MME), and by trimesters.  
Results. We included 24,731 mothers and their 24,912 live-born children of whom 7.6% (1,899) were 
exposed to prescription opioids during pregnancy. Overall, 2,138 children were diagnosed with 
neurodevelopmental disorders, with incidence rates of 42.0 per 1000 person-years in exposed children 
vs. 34.7 per 1000 person-years in unexposed children. Following adjustment for confounding, there was 
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no overall association between fetal opioid exposure and risks of neurodevelopmental disorders (HR: 
1.16 [0.99, 1.34]). However, significantly increased risks were observed in children with longer 
cumulative duration of fetal opioid exposure (adjusted HR: 1.59 [1.03, 2.45]) or high cumulative doses 
(adjusted HR: 1.25 [1.01, 1.55]). 
Conclusion and Relevance. We observed an increased risk of children neurodevelopmental disorders in 
women taking opioid for longer duration and at higher doses during pregnancy.   Additional studies are 





Pain syndromes are common during pregnancy.1,2 Maternal opioid use has steadily increased in the past 
decade, with one in every five pregnant woman estimated to receive opioids during pregnancy.3,4 
Maternal use of opioids has been associated with several negative maternal and fetal outcomes 
including altered fetal growth and congenital malformations.5–10 Birth defects have been associated with 
cognitive impairments and lower academic performance in childhood.11,12 Similar findings have also 
been reported in animal studies where exposure of rodents to opioids during critical developmental 
periods induced neuronal apoptosis,13–15 and was associated with structural and functional alterations.16  
Little is known about the effects of maternal prescription opioid use on the neurodevelopmental 
outcomes of children. So far, knowledge of the potential long-term effects of fetal opioid exposure have 
been primarily aggregated from studies investigating cognitive impairment in relationship with birth 
defects11,12 or small sample sizes conducted in women with opioid use disorders (OUD) or illicit drug use 
during pregnancy (eTable 1 in the Supplement).17–21 These findings are however not generalizable to 
offspring of mothers receiving prescribed opioids because women with OUD or a history of illicit drug 
use are more likely to have higher incidence of comorbid conditions; higher likelihood of smoking, 
cocaine, alcohol or other drug use; or socioeconomic factors that can markedly increase the risk of 
neurodevelopmental disorders in the developing fetus.19,21,22 Moreover, it is unknown whether the 
potential effects of opioids on neurodevelopment differs by trimester, cumulative dose, or duration of 
use. Therefore, we conducted a population-based study to quantify the association of gestational 
prescription opioid exposure on long-term neurodevelopmental outcomes in children.  
METHODS  
Data Source 
This study was conducted using administrative claims from January 1, 2010 to December 31, 2017 to 
Optum’s deidentified Clinformatics® Data Mart Database; a large Commercial and Medicare Advantage 
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claims database.23 This study was approved by the institutional review board of University of Rhode 
Island. Information on the algorithm for identifying deliveries, mother-infant linkage, estimation of date 
of birth and validation results using linked Rhode Island Medicaid data, opioid utilization after 
pregnancy, and timing of prenatal test screening is available in the supplementary method.  
Pregnancy Window 
The pregnancy window was defined by the estimated delivery date and last menstrual period (LMP). The 
LMP was calculated by subtracting 35 weeks for preterm births (identified using ICD-9 diagnosis codes: 
644.0, 644.2, and 765.x), and 39 weeks for full-term births from estimated delivery date.24  
Inclusion/Exclusion Criteria 
The study cohort comprised of mothers aged 12 to 55 years and their liveborn infants born between 
study start and December 31, 2012. Mothers were required to have continuous insurance eligibility 3 
months prior to the estimated LMP to one month following live birth. We excluded mothers with 
diagnosis of cancer or OUD during baseline or pregnancy;25,26 women exposed to confirmed teratogenic 
medication during pregnancy; and women or infants with ≥1 inpatient or ≥2 outpatient claims indicating 
chromosomal abnormality during pregnancy or one month after live-birth. The study cohort selection 
diagram and operational definitions for the various exclusion criteria are presented in Figure 1 and 
eTable2 respectively.  
Opioid Exposure 
Prescription opioids in our analysis included single or combination products of hydrocodone, oxycodone, 
codeine, fentanyl, hydromorphone, meperidine, methadone, oxymorphone, dihydrocodeine, 
tapentadol, levorphanol, tramadol, transdermal buprenorphine, pentazocine, or morphine. To allow 
meaningful comparisons between different opioid medications, opioid doses were converted to 
morphine milligram equivalents (MMEs) using opioid-conversion tables.27 
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Infants were considered exposed if their mother filled ≥1 opioid prescription during pregnancy and 
unexposed if their mothers did not fill a prescription of eligible opioids anytime during the baseline and 
pregnancy period. We additionally required no filling of opioid prescriptions during the baseline period 
in the reference group to prevent exposure misclassification arising from women who may still have 
opioids remaining from an earlier prescription, but available at the start of pregnancy. As such, mothers 
who filled opioids during baseline, but not during pregnancy were excluded.   
Outcome Assessment 
The primary endpoint was a composite of relevant mental disorders (henceforth regarded as 
neurodevelopmental disorders) in the infant, based on categories listed in Halloran et al.28 To facilitate 
comparison with previous research, developmental disorders - a subcategory of the primary outcome - 
was analyzed as a secondary outcome. The primary and secondary outcomes were assessed on the basis 
of the presence of ≥1 inpatient or outpatient ICD-9 or ICD-10 diagnosis in children claims (eTable 3 in the 
Supplement). Following delivery, live-birth infants born to eligible mothers before December 31, 2012 
(inclusive) were then followed until first diagnosis of neurodevelopmental disorders, lost to follow-up, or 
December 31, 2017 (the study end date), whichever came first.  
Covariates 
We considered known and suspected risk factors, and their proxies for adjustment in our analyses. The 
covariates taken into consideration were grouped as maternal sociodemographic characteristics, 
maternal comorbidities and mental health diagnoses, concomitant drug use, and measures of burden of 
illnesses such as the Obstetric Morbidity Index.29 A complete list of the covariates and the time of 
assessment is available in eTable4. 
Statistical Analysis 
Cox proportional-hazard models were used to estimate the absolute rates (per 1000 person years) and 
hazards ratio (HR) with their 95% confidence intervals. Analyses of Schoenfeld residuals showed no 
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violations of the proportional hazards assumption.30 In the adjusted analyses, we accounted for 
potential confounding by creating 50 equally sized propensity score (PS) strata based on the PS 
distribution among the opioid exposed women, and then weighted the untreated group in the final 
outcome model using the distribution of the exposed group.31 Following covariate adjustment, the 
maximum allowed standardized difference between the treatment groups was 0.1. Considering that we 
included mothers with multiple pregnancies, we accounted for correlation between siblings by using the 
Huber sandwich estimator for correction of standard errors.32 All analyses were conducted using SAS 9.4 
(SAS Institute Inc). 
Secondary analysis  
Teratogens are often dose-dependent; therefore, we evaluated for the presence of a dose-response 
relationship between fetal opioid exposure and the risk of neurodevelopmental disorders using two 
approaches. First, exposed infants were dichotomized by median cumulative opioid dose (in MME) into 
low and high cumulative dose (<37.5 and ≥37.5 MME respectively) and compared with unexposed 
infants. Second, we assessed the relationship between duration of exposure – dichotomized by 
cumulated days’ supply into “short-term” (<14 days) and “long-term exposure” (≥ 14 days) - and the 
incidence of neurodevelopmental disorders. We regarded ≥14 cumulative days of opioid use as “long-
term opioid exposure” based on previous research indicating that long-term opioid use is infrequent in 
pregnancy and the median of the total days of opioid supply during pregnancy is often less than two 
weeks.33 
Sensitivity analyses 
To our knowledge, little-to-nothing is known regarding the etiologically relevant gestational window 
between prenatal opioid exposure and neurodevelopmental disorders. Therefore, we conducted 
secondary analyses to assess the relationship between opioid exposure during specific trimesters - first 
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trimester (LMP to 90 days of pregnancy), second trimester (91 to 180 days of pregnancy), third trimester 
(181 days of pregnancy till date of birth) and the incidence of neurodevelopmental disorders.  
To address the issue of exposure misclassification during specific trimester or during pregnancy, we 
repeated our primary analyses using an alternative exposure definition based on overlapping days of 
supply. Exposure misclassification can potentially occur with our primary exposure definition if, for 
example, a mother filled an opioid prescription close to the end of a trimester but had days of supply 
from previous prescription extending into the subsequent trimester. As such, infants were considered 
exposed during pregnancy or a specific trimester if the days’ supply of opioid(s) overlapped with the 
pregnancy window or any trimester. Next, to overcome concerns of potential outcome misclassification, 
we redefined our primary outcome using two separate approaches: (a) requiring ≥2 hospital contacts for 
neurodevelopmental disorders; and (b) the presence of ≥2 neurodevelopmental disorders related claims 
on two separate days. Finally, to mitigate confounding by underlying indications for opioids, we 
performed two additional analyses. First, we repeated our primary analysis in a restricted cohort of 
children born to mothers with diagnosis of pain conditions, mental disorders or receipt of psychotropic 




Overall, 24,731 mothers with their 24,912 live-born infants were included in our analyses (Figure 1). 
There were 7.6% (n=1,899) infants exposed to prescription opioids during pregnancy. In four of every 
five exposed infants (81%, n=1,538), their mothers filled only one prescription of opioids during 
pregnancy; cumulative median dose and days of supply were 37.5 MME (2.9, 2205 MME) and 5.0 days 
(1, 392) respectively. Additional results on opioid utilization is presented in eTable5 in the Supplement. 
The median (interquartile range) and average (standard deviation (SD)) follow-up time for included 
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infants were 681 (252, 1397) and 890 (748.3) days respectively; the minimum and maximum follow-up 
time were 0 and 2558 days respectively. Prior to propensity score adjustment, compared to mothers 
who were unexposed, mothers who received opioids during pregnancy were older; generally had higher 
prevalence of tobacco use, maternal illnesses and comorbidities; and concomitant medications use 
(Table 1).   
Outcomes  
We identified 2,138 infants with neurodevelopmental disorders with 187 (9.9%) in prenatally opioid-
exposed vs. 1,951 (8.5%) in unexposed infants. The crude incidence rate among exposed and unexposed 
infants was 42.0 and 34.7 per 1000 person-years (PY) respectively, equivalent to an unadjusted HR and 
95% CI of 1.22 [1.05, 1.41]) (Table 2). Following propensity-score adjustment, the risk of 
neurodevelopmental disorders in infants exposed prenatally to opioids was further attenuated and not 
statistically significant (HR: 1.16 [0.99, 1.34]). A similar finding of no significant association following 
adjustment was observed with our secondary outcome; developmental disorders (HR: 1.10 [0.89, 1.36]) 
(Table2).  
Secondary analyses 
Children exposed to high cumulative opioid doses during pregnancy vs. unexposed children had 
increased risk of neurodevelopmental disorders (adjusted HR: 1.21 [1.01, 1.49]). Similarly, children 
whose mothers received at least 14 cumulative days’ supply of opioids had significantly increased risks 
of neurodevelopmental disorders compared with unexposed children (adjusted HR: 1.66 [1.10, 2.48]) 
(Table 3). 
Sensitivity analyses  
We observed no significant association between maternal use of opioids during any specific trimester, 
and with alternative outcome or exposure definitions (Table 3, eTable 6). Due to sample size restrictions, 
we were unable to assess the relationship between maternal opioid use during ≥2 trimesters and 
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neurodevelopmental disorders in children. When we restricted our analyses to children whose mothers 
had pain or mental disorders conditions, or received psychotropic medications, we found no significant 
association after covariate adjustment (HR: 1.16 [0.94, 1.33]). 
DISCUSSION 
Although our findings showed an absent of significantly increased risks of neurodevelopmental disorders 
in children born to mothers who received prescription opioids anytime in pregnancy, or during specific 
trimesters of pregnancy, we observed significantly increased risks of neurodevelopmental disorders in 
children whose mothers received ≥14 days’ cumulative opioid supply or higher opioid doses during 
pregnancy. These findings highlight the potential dangers of longer duration and higher doses of 
prenatal opioid exposure on children’s neurodevelopment and are consistent with the known 
dose/exposure effects of teratogens on risks for malformations and neurodevelopmental outcomes. The 
majority of prescription opioid use in pregnancy is reportedly to manage acute pain,6 often prescribed at 
lower doses or for acute use (which we also observed in the current study),33 but our findings of 
increased risks of neurodevelopmental disorders at high doses or longer duration of cumulative 
exposure have important clinical implications in women with chronic pain conditions or at risk of opioid 
abuse.  
The exact mechanism linking prenatal opioid exposure to neurodevelopmental disorders is not fully 
delineated. However, opioids are known to readily cross the placenta, are present in breast milk of 
opioid exposed mothers, and have been reported to be capable of altering fetal brain development, 
particularly in women with a history of substance abuse.16,34 Volumetric measurements of the cerebral 
characteristics of children exposed to opiates during pregnancy indicated smaller intracranial and brain 
volumes including the cerebral cortex, amygdala, brainstem, cerebellar cortex and thinner cortex of the 
right lateral orbitofrontal cortex compared to unexposed infants.35,36 Alterations of the hippocampal 
cholinergic system and opiate receptor system has also been hypothesized in literature.34,37–39 More so, 
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morphine induces apoptosis of the human microglia and neurons.34 Since several regions of the brain 
such as the limbic system, midbrain and thalamus contain the highest concentration of opioid receptors, 
it has been postulated that inappropriate activation of these receptors can alter the normal fetal brain 
development.40  
So far, evidence on this potential safety issue in human clinical studies has largely accrued from studies 
evaluating illicit heroin or methadone, mothers with diagnosis of substance misuse, drug dependence or 
OUDs, and infants with neonatal abstinence syndrome (eTable 1). Therefore, the association between 
maternal opioid exposure and the risk of neurodevelopmental disorders in the general population is 
largely unknown. Since we excluded mothers with history of OUDs and less than 0.1% of the included 
mothers in our study cohort had a history of substance misuse, it is difficult to index our findings to the 
studies previously reported in literature. To our knowledge, results at 3 and 5 years old from the 
Norwegian Mother and Child Cohort (MoBa) study by Skovlund et al evaluating maternal opioid use and 
language competencies and communications skills in children represent the only other large population-
based reports evaluating this safety concern.41,42 The authors reported no significant association 
between prenatal opioid exposure and impairments in language competencies and communications 
skills in children at 3 or 5 years of age, but noted that their study could not address opioid use with large 
doses or long duration during pregnancy. While the results of our overall analysis are similar to the two 
reports by Skovlund et al, the current study is different in a few ways. Unlike in Skovlund’s studies, we 
did not rely on self-reports to assess exposure status or the incidence of neurodevelopmental outcomes 
in children. While parental self-reporting is generally regarded as a valid tool for measuring 
neurocognitive disorders in children,43,44 there is increased propensity for recall bias with self-reported 
exposure. Moreover, differences between self-reported use of opioids during pregnancy compared to 
dispensing information available in prescription records has been reported in the MoBa cohort.45 
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Additionally, neurocognitive disorders in early childhood can occur as a constellation of overlapping 
symptoms such that restricting to language disorders, while clinically relevant, may be too restrictive.  
The current study has several strengths. First, our study provides updated information on the utilization 
of opioids during pregnancy and extends the limited knowledge in literature on the risks associated with 
in-utero opioid exposure in children. Second, we utilized a relatively large population size, utilized a 
specific exposure definition and diagnoses for neurodevelopmental disorders as well as performed 
several additional analyses to mitigate confounding and to assess the robustness of our findings. Most 
importantly, our study provides much-needed data on relationship between cumulative dose, timing of 
exposure, and duration of use of opioids during pregnancy and the risk of neurodevelopmental 
disorders in children; information otherwise missing in the literature.  
There are several limitations in the current study. Considering that administrative claims are not always 
reported with fidelity, measurement errors including outcome and exposure misclassification may have 
occurred, although more likely to be nondifferential. For example, exposure misclassification arising 
from the use of unprescribed or illicit opioids may have occurred. Nevertheless, the observed strength 
of association between our primary outcome and overall conclusions did not appreciably change with 
alternative exposure or more conservative outcome definitions. Second, presence of 
neurodevelopmental disorders is a dichotomous measure. It may therefore miss cognitive declines that 
do not rise to the level of a diagnosis and may have less power compared to objective continuous 
measures of cognitive abilities such as intelligence quotient (IQ). For example, in the NEAD study that 
demonstrated robust effects of valproate on IQ, an analysis for the dichotomous measure of mental 
retardation (i.e., <70 IQ) was not significant.46 As such, studies involving objective measures of cognitive 
performance are needed to further evaluate this potential safety concern.  
Despite our best efforts to address confounding by known and suspected confounders, our study results 
may still be impacted by residual or unmeasured confounding arising from inadequate adjustments or 
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incomplete information on important confounders such as maternal use of folic acid, breastfeeding 
patterns after delivery, lifestyle factors such as alcohol drinking during pregnancy, severity of pain, and 
heritability. Fourth, a variable that specifically captures the actual date of birth is absent from our data 
set. While we relied on validated algorithms to estimate the pregnancy period,47,48 and results from the  
replication of these methods in a database with clinically-documented date of birth (Supplementary 
method/results) indicated the absence of substantial bias, our estimation of the pregnancy window may 
still be prone to measurement error, albeit minimal. Fifth, although we included a relatively large 
number of mother-infant pairs, we observed low rates of neurodevelopmental disorders in children; 
thus, there is the concern of limited statistical power. Additionally, our findings may have been impacted 
by the relatively short duration of follow-up (about 2 years) as some relevant neurodevelopmental 
outcomes may go undetected in early infancy until later in childhood. Conversely, we may have 
inaccurately included false positives; that is, individuals who experienced improvements in intellectual 
and cognitive function later in childhood.  
Finally, our study population comprises predominantly of mothers and children potentially of higher 
socioeconomic status or those eligible for enrollment in private health plans. Therefore, our findings 
may not be generalizable to uninsured or Medicaid enrolled mothers who are typically of lower 
socioeconomic status and thus may have a higher prevalence of risk factors predisposing children to 
higher risks of neurodevelopmental disorders. This specific limitation is however unrelated to the 
internal validity of our study.  
Conclusions 
Although our overall results indicate the absence of a significant association, offspring of exposed 
mothers prescribed opioids for a longer period or at higher cumulative dose during pregnancy had 
significantly increased risk of neurodevelopmental disorders. These findings emphasize the need for 
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careful evaluation of risks versus potential benefits in pregnant women requiring long-term opioid 
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Mothers (n = 208, 185) and their 
live-born infants (n = 214, 270) 
Mothers without diagnosis of 
cancer (n = 207, 190) 
Mothers with non-rule-out cancer 
during baseline and pregnancy 
period (n = 995) 
Mothers with non-continuous 
enrollment during baseline through 
one-month post-partum (n = 146, 
125)  
(mothers = 355,66 ; infants = 393, 
000) 
Mothers with no history of opioid 
use disorder (n = 1,154) 
Receipt of confirmed teratogenic 
drugs or chromosomal 
abnormalities during pregnancy in 
mothers (n = 675) or during 
pregnancy till one month after birth 
(n = 699) 
 
Women who filled opioids during 
baseline period, but not during 
pregnancy (n = 3, 427) 
Analysis cohort  
24, 912 babies born to 24, 731 
eligible mothers by December 31, 
2012  
 
Mothers with no receipt of confirmed 
teratogenic drugs or chromosomal 
abnormalities during pregnancy 
(mothers = 59, 236) 
Mothers with no history of opioid 
use disorder (n = 59, 911) 
Mothers with continuous enrollment 
during baseline through one-month 
post-partum (n = 61, 065) 
Eligible mothers in study cohort  
(n = 55, 809) 
Mothers with live-birth after  
1 January 2013 (n = 31, 078) 
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Table 1: Selected baseline characteristics of women by maternal prescription opioid use    














Maternal age at delivery          
Mean age, SD 30.7 (4.3) 30.5 (4.1) 0.040 30.7 (4.3) 30.7 (4.2) -0.040 
< 18 3 (0.2) 51 (0.2) -0.015 3 (0.2) 36 (0.2) 0.000 
18 - 24 124 (6.5) 1421 (6.2) 0.015 124 (6.5) 1517 (6.6) -0.003 
25 - 34 1464 (77.1) 18292 (79.5) -0.058 1462 (77.1) 17664 (76.9) 0.003 
≥ 35  308 (16.2) 3249 (14.1) 0.059 308 (16.2) 3742 (16.3) -0.002 
Year of birth             
2010 3 (0.2) 49 (0.2) -0.013 3 (0.2) 35 (0.2) 0.001 
2011 1057 (55.7) 12171 (52.9) 0.056 1056 (55.7) 12909 (56.2) -0.011 
2012 839 (44.2) 10793 (46.9) -0.055 838 (44.2) 10015 (43.6) 0.011 
Geographic region             
Northeast 71 (3.7) 1495 (6.5) -0.125 70 (3.7) 892 (3.9) -0.010 
Midwest 483 (25.4) 6587 (28.6) -0.072 482 (25.4) 5751 (25) 0.008 
South 782 (41.2) 8676 (37.7) 0.071 782 (41.2) 9387 (40.9) 0.007 
West  553 (29.1) 6157 (26.8) 0.053 553 (29.2) 6813 (29.7) -0.011 
Unknown 10 (0.5) 98 (0.4) 0.015 10 (0.5) 117 (0.5) 0.002 
Obstetric characteristics             
Tobacco use 50 (2.6) 319 (1.4) 0.089 50 (2.6) 601 (2.6) 0.002 
Obesity  66 (3.5) 615 (2.7) 0.047 66 (3.5) 820 (3.6) 0.014 
Multiple gestation 9 (0.5) 58 (0.3) 0.037 9 (0.5) 108 (0.5) 0.000 
Substance use and abuse 2 (0.1) 10 (0) 0.023 2 (0.1) 22 (0.1) -0.010 
Obesity  66 (3.5) 615 (2.7) 0.047 66 (3.5) 820 (3.6) 0.014 
Comorbid conditions             
Psychiatric conditions             
Depression 123 (6.5) 797 (3.5) 0.139 122 (6.4) 1459 (6.4) 0.028 
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Anxiety  108 (5.7) 856 (3.7) 0.093 107 (5.6) 1263 (5.5) 0.024 
ADHD 26 (1.4) 164 (0.7) 0.065 26 (1.4) 315 (1.4) -0.002 
Bipolar disorder 10 (0.5) 39 (0.2) 0.061 9 (0.5) 112 (0.5) 0.018 
Epilepsy 4 (0.2) 33 (0.1) 0.016 4 (0.2) 46 (0.2) 0.017 
ADHD 26 (1.4) 164 (0.7) 0.065 26 (1.4) 315 (1.4) -0.002 
Pain conditions             
Fibromyalgia 52 (2.7) 417 (1.8) 0.062 52 (2.7) 628 (2.7) 0.004 
Migraine 196 (10.3) 934 (4.1) 0.244 195 (10.3) 2330 (10.2) 0.005 
Back pain 510 (26.9) 3707 (16.1) 0.264 510 (26.9) 6407 (27.9) -0.019 
Other maternal illnesses             
Diabetics 29 (1.5) 302 (1.3) 0.018 29 (1.5) 344 (1.5) -0.011 
Hypertension 44 (2.3) 321 (1.4) 0.068 44 (2.3) 522 (2.3) 0.010 
Renal disease 12 (0.6) 57 (0.2) 0.058 12 (0.6) 144 (0.6) 0.001  
Concomitant medication use             
Psychotropic medications             
Benzodiazepines 121 (6.4) 504 (2.2) 0.208 120 (6.3) 1392 (6.1) 0.018 
Antidepressants 240 (12.6) 1323 (5.7) 0.240 239 (12.6) 2870 (12.5) 0.030 
Psychostimulants 44 (2.3) 248 (1.1) 0.096 44 (2.3) 522 (2.3) 0.005 
 Antipsychotics 5 (0.3) 36 (0.2) 0.023 4 (0.2) 57 (0.2) -0.003 
Other medications             
Antidiabetics 57 (3) 430 (1.9) 0.074 57 (3) 693 (3) -0.005 
Antihypertensives 79 (4.2) 467 (2) 0.123 79 (4.2) 898 (3.9) 0.022 
Antiepileptics 38 (2) 141 (0.6) 0.122 37 (2) 393 (1.7) 0.028 
Maternal comorbidity makers             
Maternal comorbidity index, mean (SD) 0.4 (0.8) 0.3 (0.7) 0.068 0.4 (0.8) 0.4 (0.8) 0.015 
Number of hospitalizations 1.2 (2.7) 1.1 (1.9) 0.039 1.2 (2.7) 1.2 (2.7) 0.023 
Length of hospitalization, mean (SD) 0.4 (0.5) 0.5 (0.5) -0.043 0.4 (0.5) 0.4 (0.5) 0.031 
Number of outpatient visits, mean (SD) 33.4 (25) 30.9 (24.2) 0.100 33.4 (25.0) 32.7 (26.8) 0.027 
Abbreviations. ADHD, attention-deficit hyperactivity disorder; PS, propensity scores. Unless otherwise stated, number (%) are presented.    
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Table 2: Hazards ratio of the risk of neurodevelopmental disorders in children by maternal exposure to opioids   
Outcome Total number Cases, n (%) Incidence rate per 1000 PY Crude HR (95% CI) Adjusted HR (95% CI) a 
Neurodevelopmental disorders      
Unexposed  23013 1951 (8.5) 34.7 1 1 
Exposed 1899 187 (9.9) 42.0 1.22 (1.05, 1.41) 1.16 (0.99, 1.34) 
Developmental disorders      
Unexposed  23013 1292 22.9 1 1 
Exposed  1899 120 26.9 1.17 (0.97, 1.42) 1.10 (0.89, 1.36) 
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Table 3: Sensitivity analyses of the risk of neurodevelopmental disorders in children by maternal opioid use  
Additional analyses Total number  Case IR per 1000 
PY 
Unadjusted HR Adjusted HR a 
Timing of exposure during pregnancy        
Unexposed 23013 1951  34.7 1 1 
First trimester alone 653 66 42.7 1.23 (0.98, 1.58) 1.10 (0.86, 1.41) 
Second trimester alone 395 36 39.8 1.15 (0.83, 1.62) 1.11 (0.80, 1,54) 
Third trimester alone  672 66 41.3 1.19 (0.94, 1.54) 1.20 (0.94, 1.54) 
Cumulative duration of use during pregnancy        
Unexposed 23013 1951  34.7 1 1 
Less than 14 days 1717 163 40.2 1.20 (1.03, 1.40) 1.12 (0.95, 1.31) 
At least 14 days 182 24 59.0 1.72 (1.16, 2.53) 1.66 (1.10, 2.48) 
Cumulative dose b      
Unexposed 23013 1951  34.7 1 1 
Low dose (<37.5 MME) 986 88 38.8 1.14 (0.92, 1.40) 1.10 (0.87, 1.36) 
High dose (≥37.5 MME) 913 99 45.3 1.36 (1.12, 1.65) 1.21 (1.01, 1.49) 
Alternative outcome definitions        
>= 2 mental disorder claims       
Unexposed 23013 1462  26.0 1 1 
Exposed 1899 133 29.8 1.15 (0.97, 1.38) 1.10 (0.91, 1.35) 
>=2 mental disorders claims filled on >=2 separate days       
Unexposed 23013 1023  18.2 1 1 
Exposed 1899 89 20.0 1.10 (0.89, 1.37) 1.06 (0.84, 1.34) 
Analysis in restricted cohort with diagnosis of pain or 
mental disorders, or receipt of psychostimulants       
Unexposed 12337 823 27.8 1 1 
Exposed 1246 95 32.9 1.20 (1.01, 1.44) 1.16 (0.94, 1.44) 
Abbreviations. HR: hazards ratio; IR: incidence rate; PY: person-years; MME: morphine milligram equivalent. a Adjusted HRs and 95% CI were 
obtained using propensity score by fine stratification. b Fetal cumulative opioid exposure was categorized by median split of the total opioid 
doses during pregnancy. The low and high categories correspond to 2.25 – 37.4 MME and 37.5 – 2250 MME respectively.   
 
